About: ACE‐inhibitors and Angiotensin‐2 Receptor Blockers are not associated with severe SARS‐COVID19 infection in a multi‐site UK acute Hospital Trust

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ACE‐inhibitors and Angiotensin‐2 Receptor Blockers are not associated with severe SARS‐COVID19 infection in a multi‐site UK acute Hospital Trust Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	ACE‐inhibitors and Angiotensin‐2 Receptor Blockers are not associated with severe SARS‐COVID19 infection in a multi‐site UK acute Hospital Trust
Creator	Shah, Ajay Bean, Daniel Bendayan, Rebecca Dobson, Richard Folarin, Amos Noor, Kawsar O'gallagher, Kevin Pickles, Andrew Roguski, Lukasz Searle, Thomas Shek, Anthony Teo, James Zakeri, Rosita Kraljevic,
source	Medline; PMC
abstract	AIMS: The SARS‐Cov2 virus binds to the ACE2 receptor for cell entry. It has been suggested that ACE‐inhibitors (ACEi) and Angiotensin‐2 Blockers (ARB), which are commonly used in patients with hypertension or diabetes and may raise tissue ACE2 levels, could increase the risk of severe COVID19 infection. METHODS AND RESULTS: We evaluated this hypothesis in a consecutive cohort of 1200 acute inpatients with COVID19 at two hospitals with a multi‐ethnic catchment population in London (UK). The mean age was 68 ± 17 years (57% male) and 74% of patients had at least 1 comorbidity. 415 patients (34.6%) reached the primary endpoint of death or transfer to a critical care unit for organ support within 21‐days of symptom onset. 399 patients (33.3%) were taking ACEi or ARB. Patients on ACEi/ARB were significantly older and had more comorbidities. The odds ratio (OR) for the primary endpoint in patients on ACEi and ARB, after adjustment for age, sex and co‐morbidities, was 0.63 (CI 0.47–0.84, p < 0.01). CONCLUSIONS: There was no evidence for increased severity of COVID19 disease in hospitalised patients on chronic treatment with ACEi or ARB. A trend towards a beneficial effect of ACEi/ARB requires further evaluation in larger meta‐analyses and randomised clinical trials. This article is protected by copyright. All rights reserved.
has issue date	2020-06-02(xsd:dateTime)
bibo:doi	10.1002/ejhf.1924
bibo:pmid	32485082
has license	no-cc
sha1sum (hex)	e2083005201450b84a2820f34e85afb508f497e6
schema:url	https://doi.org/10.1002/ejhf.1924
resource representing a document's title	ACE‐inhibitors and Angiotensin‐2 Receptor Blockers are not associated with severe SARS‐COVID19 infection in a multi‐site UK acute Hospital Trust
has PubMed Central identifier	PMC7301045
has PubMed identifier	32485082
schema:publication	Eur J Heart Fail
resource representing a document's body	covid:e2083005201450b84a2820f34e85afb508f497e6#body_text
is schema:about of	named entity 'Angiotensin' named entity 'Blockers' named entity 'Trust' named entity 'infection' named entity 'virus' named entity 'ACE2' named entity 'ACE2 receptor' named entity 'cell entry' named entity 'Blockers' named entity 'Angiotensin-2' named entity 'COVID19' named entity 'COVID19' named entity 'Angiotensin-2 Receptor Blockers' named entity 'SARS' named entity 'acute Hospital' named entity 'ACEi' named entity 'fever' named entity 'COVID19' named entity 'ACEi' named entity 'Critical Care Unit' named entity 'comorbidities' named entity 'myalgia' named entity 'London' named entity 'comorbidities' named entity 'heart failure' named entity 'SARS-CoV2' named entity 'strength of association' named entity 'hypertension' named entity 'King's College Hospital' named entity 'epithelial cells' named entity 'ethnicity' named entity 'hypertension' named entity 'chronic kidney disease' named entity 'cell surface' named entity 'COVID19' named entity 'randomised control trials' named entity 'diabetes' named entity 'SARS-CoV2' named entity 'Africa' named entity 'high volume' named entity 'ACEi' named entity 'western world' named entity 'COVID19' named entity 'ischaemic heart disease' named entity 'ACEi' named entity 'COVID19' named entity 'emergency department' named entity 'ACE2 receptor' named entity 'Acute Respiratory Distress Syndrome' named entity 'COVID-19 disease' named entity 'hypertension' named entity 'Odds Ratio' named entity 'ACEi' named entity 'ACE2' named entity 'ACEi' named entity 'ratio scale' named entity 'ACEi' named entity 'comorbidities' named entity 'hypertension' named entity 'critical care' named entity 'older age' named entity 'chronic kidney disease' named entity 'Odds Ratio' named entity 'ACEi' named entity 'ACEi' named entity 'ACEi' named entity 'cardiovascular' named entity 'COVID19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software